Venous Thromboembolism MarketSize and Trends

Global venous thromboembolism market taxonomy

The global market is segmented on the basis of product type and disease type. On the basis of product type, the market is segmented as follows:

Drug therapy

Heparin
Apixaban
Dabigatran
Rivaroxaban
Edoxaban
Warfarin

Devices
Thrombolytic therapy

Heparin has been the gold standard for treating VTE. In a recent study published (2017) in the New England Journal of Medicine, Rivaroxaban has shown to be more effective in reducing the risk of recurrent events in patients with venous thromboembolism in equipoise with continued anticoagulation medications compared to Aspirin. Devices used for treating VTE include compression stockings, and intermittent pneumatic compression devices. Thrombolytic therapy includes administering tissue plasminogen activator.

Innovative treatment and drugs to fuel growth of global venous thromboembolism market

The APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) trial reported in March 2017 that extended use of betrixaban post parenteral prophylaxis with enoxaparin lowers the VTE incidence among patients discharged from hospital. Currently, there no anticoagulants approved for extended-duration use in patients after hospital discharge and in those who are at high risk of VTE. This treatment approach could significantly benefit those patients and be a growth contributor for the global venous thromboembolism market.